Drug Information

Drug (ID: DG00856) and It's Reported Resistant Information

• Name: Proflavine
• Synonyms: Proflavine; acridine-3,6-diamine; Proflavin; 92-62-6; 3,6-Diaminoacridine; 3,6-ACRIDINEDIAMINE; Isoflav base; Proflavine hemisulfate; Proflavina; Proflavinum; 2,8-Diaminoacridinium; Acridine, 3,6-diamino-; 3,6-Diaminoacridinium; 3,7-Diamino-5-azaanthracene; 2,8-Diaminoacridine; UNII-CY3RNB3K4T; 1811-28-5; Proflavine (hemisulfate); CY3RNB3K4T; CHEBI:8452; Proflavine [INN]; Profura; Progarmed; Proflavinum [INN-Latin]; PRL; Proflavina [INN-Spanish]; Proflavin hemisulfate;3,6-Diaminoacridine hemisulfate; 2,8-Diaminoacridine (European); CCRIS 1244; MFCD00149650; HSDB 7071; NCGC00166245-01; EINECS 202-172-4; BRN 0166050; AI3-52128; 1bcu; 1qvt; 1qvu; 3,6-Acridinediamine hydrochloride; 3,6-diaminoacridin; 3,6-Diaminoacridine hemisulfate salt; proflavine-hemisulfate; NCIMech_000209; SCHEMBL27386; 5-22-11-00322 (Beilstein Handbook Reference); AE-562/12222295; CHEMBL55400; Proflavine;3,6-Diaminoacridine; SCHEMBL8149677; YSCH0132; DTXSID9043776; BDBM12590; WDVSHHCDHLJJJR-UHFFFAOYSA-; 2v57; Proflavine hemisulfate salt hydrate; 3,6-diamino acridine hydrochloride; ALBB-024962; HY-B1741; ZINC3775644; MFCD00005030; STK380650; AKOS005449844; AT13412; CCG-339542; DB01123; MCULE-9362278105; NCGC00166245-02; NCI60_004643; NCI60_004767; NCI60_032077; CS-0013756; S5776; AB00375967-03; AB00375967_04; (6-aminoacridin-3-yl)amine;sulfuric acid;hydrate; A909942; Q420454; SR-01000883943; SR-01000883943-1; UNII-1T3A50395T component WDVSHHCDHLJJJR-UHFFFAOYSA-N
• Indication:
  In total 1 Indication(s)
  Sepsis [ICD-11: 1G40]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Pneumonia [ICD-11: CA40]; [1]
• Target: Bacterial Deoxyribonucleic acid (Bact DNA); NOUNIPROTAC; [1]
• Formula: C13H11N3
• IsoSMILES: C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N
• InChI: 1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2
• InChIKey: WDVSHHCDHLJJJR-UHFFFAOYSA-N
• PubChem CID: 7099
• ChEBI ID: CHEBI:8452
• TTD Drug ID: D08GSF
• DrugBank ID: DB01123

Type(s) of Resistant Mechanism of This Drug

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-12: Respiratory system diseases

Pneumonia [ICD-11: CA40]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: Short-chain diamines transporter (PACE) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Klebsiella pneumoniae infection [ICD-11: CA40.1]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Burkholderia cenocepacia HI2424; 95486
• In Vitro Model: Klebsiella pneumoniae 342; 573
• In Vitro Model: Pseudomonas syringae pv. Tomato strain DC3000; 323
• In Vitro Model: Vibrio parahaemolyticus strain; 670
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Broth dilution assay
• Mechanism Description: The novel AceI (Acinetobacter chlorhexidine efflux) protein from Acinetobacter baumannii that conferred resistance to the biocide chlorhexidine, via an active efflux mechanism. MIC analyses demonstrated that, like AceI, many of the homologs conferred resistance to chlorhexidine. Many of the AceI homologs conferred resistance to additional biocides, including benzalkonium, dequalinium, proflavine, and acriflavine.

References

• Ref 1: Homologs of the Acinetobacter baumannii AceI transporter represent a new family of bacterial multidrug efflux systems .mBio. 2015 Feb 10;6(1):e01982-14. doi: 10.1128/mBio.01982-14. 10.1128/mBio.01982-14